Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 63

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 63
---
 2025 GM and our shareholders passed resolutions to, among other things, subdivide our Ordinary Shares of £0.00005 nominal
value each into one Ordinary Share of £0.000001 nominal value and 49 D Deferred Shares of £0.000001 nominal value each.

On July 31, 2025, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 10,000 Ordinary Shares per Depositary Share
to 100,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

Options

We have established the Biodexa
Pharmaceuticals PLC Enterprise Management Incentive and Unapproved Option Scheme to allow us to grant options to purchase Ordinary Shares (in the form of Depositary Shares) to employees and directors of the Company or any of its subsidiaries for the purpose of attracting, rewarding and retaining such persons. The Plan was originally adopted in December 2014 and amended on April 11, 2024 to govern the grant of tax-advantaged enterprise management incentive stock options and unapproved stock options by the Company. As of June 30, 2025, there were options to purchase 313,070,788Ordinary Shares. The options lapse after ten years from the date of
the grant. As of June 30, 2025, the weighted average remaining life of the options was 8.7 years.

In connection with our acquisition
of DARA Biosciences, Inc., or DARA, in December 2015, we assumed all of DARA’s outstanding options, or DARA Options. As of June
30, 2025, there were outstanding DARA Options to purchase six Ordinary Shares with a weighted average remaining life of 0.3 years.

| 38 |

Warrants

February Placement Agent Warrants

The following is a brief summary
of the February Placement Agent Warrants, and is subject in all respects to the provisions contained in the warrant, which is filed as
an exhibit to our Report on Form 6-K dated February 9, 2023.

Exercisability.The
February Placement Agent Warrants are exercisable and expire three years from the initial exercise date. The holder shall deliver the
aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise
(subject to the ‘cashless exercise’ arrangements described below).

Cashless Exercise.The
February Placement Agent Warrants may only be exercised